1. Scrip
  2. >>Business

Pierre Fabre Boosts Oncology Offering In Europe With Puma Deal

 
• By John Davis

Another major deal with a US biotech has seen France’s Pierre Fabre exclusively licensing Puma’s Nerlynx for development and commercialization in Europe.  

Mountains
The agreement covers countries in North Africa, too. • Source: Shutterstock

Oncology R&D and commercialization are priorities for drugs-to-cosmetics firm Pierre Fabre Group, and the Castres, France-based private company has entered into its second major anticancer deal with a US biotech in recent years, this time with Los Angeles-headquartered Puma Biotechnology Inc..

Pierre Fabre has exclusively licensed Puma’s kinase inhibitor, Nerlynx (neratinib), approved for EU marketing in September 2018, for development and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.